化合物E7820 T4435
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
200 mg | 289483-69-8 | ¥5,120.00 | 询底价 |
1 mL | 289483-69-8 | ¥867.00 | 询底价 |
2 mg | 289483-69-8 | ¥473.00 | 询底价 |
5 mg | 289483-69-8 | ¥625.00 | 询底价 |
50 mg | 289483-69-8 | ¥2,230.00 | 询底价 |
25 mg | 289483-69-8 | ¥1,490.00 | 询底价 |
10 mg | 289483-69-8 | ¥828.00 | 询底价 |
1 mg | 289483-69-8 | ¥352.00 | 询底价 |
100 mg | 289483-69-8 | ¥3,590.00 | 询底价 |
Product Introduction
Bioactivity
英文名: E7820
描述: E7820 (ER68203-00) 是具有口服活性芳香族磺酰胺衍生物,是一种血管生成抑制剂,可抑制内皮上整合素 α2 亚基的表达。它调节 α1,α2,α3 和 α5 整联素 mRNA 表达,具有抗血管生成和抗肿瘤活性。它抑制大鼠主动脉血管生成,IC50为 0.11 μg/ml。
体外活性: E7820 inhibits proliferation of HUVEC induced by either bFGF (IC50: 0.10 μg/mL) and VEGF (IC50: 0.081 μg/mL) in serum-free medium. E7820 also inhibits both bFGF- (IC50: 0.20 μg/mL) and VEGF-driven (IC50: 0.24 μg/mL) tube formation of HUVEC in this assay[3].
体内活性: E7820 (50 mg/kg) with erlotinib has a significantly synergistic antitumor effect in three xenograft models without severe body weight loss. E7820 (50 mg/kg) and erlotinib decrease MVD and enhance apoptosis in tumor-associated endothelial cells, inhibit tumor cell proliferation and enhanced apoptosis, and enhance inhibition of cell proliferation and apoptosis through activation of both intrinsic and extrinsic apoptosis pathways in human NSCLC xenograft models[1]. E7820 shows anti-tumor activity at doses of 50, 100, and 200 mg/kg in the tumor growth and α2-integrin expression experiments[2]. E7820 (50, 100, and 200 mg/kg) inhibits tumor growth in a dose-dependent manner in all s.c. xenograft models. E7820 completely inhibits s.c. tumor growth of LoVo tumor cells and also regresses the tumor mass of KP-1 tumor cells at the dosages of both 100 and 200 mg/kg[3].
存储条件: store at low temperaturePowder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : Insoluble
DMSO : 33 mg/mL
关键字: cell | tumor | E 7820 | WiDr | derivative | Integrin | E7820 | colorectal | LoVo | inhibit | Inhibitor | sulfonamide | HUVEC | E-7820 | endothelium
相关产品: CWHM-12 | A-286982 | RWJ 50271 | Vaccarin | SB273005 | iRGD peptide | β-glycosidase-IN-1 | PLN-1474 | ILK-IN-2 | Gly-Arg-Gly-Asp-Ser acetate(96426-21-0 free base)
相关库: Drug Repurposing Compound Library | Anti-Cancer Compound Library | Angiogenesis related Compound Library | Anti-Cancer Drug Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Colorectal Cancer Compound Library | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Active Compound Library | Orally Active Compound Library
化合物E7820 T4435信息由TargetMol中国为您提供,如您想了解更多关于化合物E7820 T4435报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途